Khava B. Kodzoeva

Khava B. Kodzoeva

Auto-generated profile, based on publicly available information

Khava B. Kodzoeva

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
MMM. V. Maevskaya
M. V. Maevskaya
ZMZharkova Maria
Zharkova Maria
YKYu. V. Kotovskaya
Yu. V. Kotovskaya
OTO. N. Tkacheva
O. N. Tkacheva
АМА. Ю. Майоров
А. Ю. Майоров
Aim:present clinical guidelines, aimed at general practitioners, gastroenterologists, cardiologists, endocrinologists, comprise up-to-date methods of diagnosis and treatment of non-alcoholic fatty liver disease.Key points.Nonalcoholic fatty liver disease, the most wide-spread chronic liver disease, is characterized by accumulation of fat by more than 5 % of hepatocytes and presented by two histological forms: steatosis and nonalcoholic steatohepatitis. Clinical guidelines provide current views on pathogenesis of nonalcoholic fatty liver disease as a multisystem disease, methods of invasive and noninvasive diagnosis of steatosis and liver fibrosis, principles of nondrug treatment and pharmacotherapy of nonalcoholic fatty liver disease and associated conditions. Complications of nonalcoholic fatty liver disease include aggravation of cardiometabolic risks, development of hepatocellular cancer, progression of liver fibrosis to cirrhotic stage.Conclusion.Progression of liver disease can be avoided, cardiometabolic risks can be reduced and patients' prognosis — improved by the timely recognition of diagnosis of nonalcoholic fatty liver disease and associated comorbidities and competent multidisciplinary management of these patients.

15 February 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
MMM V Maevskaya
M V Maevskaya
YKY V Kotovskaya
Y V Kotovskaya
VIVladimir Ivashkin
Vladimir Ivashkin
OTO N Tkacheva
O N Tkacheva
ETEkaterina Troshina
Ekaterina Troshina
MSM S Shamkhalova
M S Shamkhalova
The National Consensus was prepared with the participation of the National Medical Association for the Study of the Multimorbidity, Russian Scientific Liver Society, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians, National Society for Preventive Cardiology, Professional Foundation for the Promotion of Medicine Fund PROFMEDFORUM. The aim of the multidisciplinary consensus is a detailed analysis of the course of non-alcoholic fatty liver disease (NAFLD) and the main associated conditions. The definition of NAFLD is given, its prevalence is described, methods for diagnosing its components such as steatosis, inflammation and fibrosis are described. The association of NAFLD with a number of cardio-metabolic diseases (arterial hypertension, atherosclerosis, thrombotic complications, type 2 diabetes mellitus, obesity, dyslipidemia, etc.), chronic kidney disease and the risk of developing hepatocellular cancer were analyzed. The review of non-drug methods of treatment of NAFLD and modern opportunities of pharmacotherapy are presented. The possibilities of new molecules in the treatment of NAFLD are considered: agonists of nuclear receptors, antagonists of pro-inflammatory molecules, etc. The positive properties and disadvantages of currently used drugs (vitamin E, thiazolidinediones, etc.) are described. Special attention is paid to the multi-target ursodeoxycholic acid molecule in the complex treatment of NAFLD as a multifactorial disease. Its anti-inflammatory, anti-oxidant and cytoprotective properties, the ability to reduce steatosis an independent risk factor for the development of cardiovascular pathology, reduce inflammation and hepatic fibrosis through the modulation of autophagy are considered. The ability of ursodeoxycholic acid to influence glucose and lipid homeostasis and to have an anticarcinogenic effect has been demonstrated. The Consensus statement has advanced provisions for practitioners to optimize the diagnosis and treatment of NAFLD and related common pathogenetic links of cardio-metabolic diseases.

31 January 2020 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
MMM. V. Mayevskaya
M. V. Mayevskaya
MNMaria Nadinskaia
Maria Nadinskaia
ВЛВ. Д. Луньков
В. Д. Луньков
IPI. Yu. Pirogova
I. Yu. Pirogova
ECE. V. Chesnokov
E. V. Chesnokov
VIVladimir Ivashkin
Vladimir Ivashkin
Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ

9 March 2025 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
ODOxana M. Drapkina
Oxana M. Drapkina
MMM. V. Maevskaya
M. V. Maevskaya
KRK. L. Raikhelson
K. L. Raikhelson
SOSergey Okovityi
Sergey Okovityi
ЮУЮ. П. Успенский
Ю. П. Успенский
Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with non-alcoholic fatty liver disease, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of nonalcoholic fatty liver disease, peculiarities of its clinical course. Also given recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for nonalcoholic fatty liver disease and its clinical phenotypes assessment, approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician's actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with nonalcoholic fatty liver disease contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.

15 February 2019 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
MNMaria Nadinskaia
Maria Nadinskaia
KKKh. B. Kodzoeva
Kh. B. Kodzoeva
KUK. A. Ulyanova
K. A. Ulyanova
SRS. I. Rogacheva
S. I. Rogacheva
AVA. S. Volkova
A. S. Volkova
VIVladimir Ivashkin
Vladimir Ivashkin
Portal vein thrombosis (PVT) in patients with liver cirrhosis is a common complication associated with adverse outcomes. Aim. To build a predictive model for PVT in cirrhotic patients. Materials and methods. A single centre case-control study was carried out. From the database of 1512 cirrhotic patients 94 with newly diagnosed PVT based on contrast-enhanced computed tomography were referred to the Case group. Malignant PVT was an exclusion criterion. Patients without PVT were stratified and matched according to sex, age and etiology of cirrhosis; case-control ratio was 1 : 3–4. The prevalence of PVT in the database, clinical, laboratory, instrumental parameters of the groups were evaluated. Logistic regression model was used to estimate association between variables and PVT. Results and discussion. The overall prevalence of PVT was 6.2% with the highest rates among the patients with HBV infection – 16.7%, nonalcoholic steatohepatitis – 15.6%, alcohol abuse in combination with HCV infection – 11.7%. The best predictive model included variables: Child-Pugh classes B–C (coefficient of regression β=1.853, р=0.001), ascites (β=0.460, р=0.003), hepatocellular carcinoma without vascular invasion (β=2.126, р=0.0001), endoscopic band ligation (β=0.774, р=0.003), azygoportal disconnection (β=2.734, р=0.001), portal hypertensive gastropathy (β=0.793, р=0.017), portal vein diameter (β=0.203, р=0.004), and local factors – ulcerative colitis flare, Clostridium difficile enterocolitis, spontaneous bacterial peritonitis, colorectal cancer, splenectomy, cholecystectomy (β=2.075, р=0.017). The model had accuracy 85.8% (95% CI 81.7–89.4%), sensitivity – 55.1% (95% CI 43.4–66.4%), specificity – 95% (95% CI 91.6–97.3%), and AUC – 0.871 (95% CI 0.826–0.916). Conclusion. Child-Pugh classes B–C, severe portal hypertension, hepatocellular carcinoma without vascular invasion, and local factors were estimated as risk factors of PVT in cirrhotic patients. Keywords: portal vein thrombosis, liver cirrhosis, case-control study, Child-Pugh class, portal hypertension, hepatocellular carcinoma, local factors, logistic regression model

1 May 2021 in Sechenov Medical Journal
Verified
Journal Article
Open access
PDF file
NBNikolay Bulanov
Nikolay Bulanov
OBOleg Blyuss
Oleg Blyuss
DMDaniel Munblit
Daniel Munblit
NNN. A. Nekliudov
N. A. Nekliudov
DBD. V. Butnaru
D. V. Butnaru
МНМ. Ю. Надинская
М. Ю. Надинская
Adequate design is an essential condition for conducting a successful study. This review describes the most common types of research design in medicine. We discuss the differences between different types of observational and interventional studies, their advantages and limitations providing examples for each study design. The concept of bias and its potential sources in different studies are covered. We suggest the most suitable approaches to study design for different research objectives and outline approaches to data presentation. During the last decades, several guidelines for conducting and reporting different types of research were proposed and they are also covered in this manuscript.